Leonteq Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$134K Sell
2,227
-1,371
-38% -$86.3K 0.01% 601
2026
Q2
$206K Buy
3,598
+127
+4% +$6.96K 0.01% 564
2026
Q1
$196K Sell
3,471
-2,242
-39% -$131K 0.01% 604
2025
Q4
$340K Sell
5,713
-20,837
-78% -$1.13M 0.01% 547
2025
Q3
$1.44M Buy
26,550
+21,784
+457% +$1.25M 0.04% 240
2025
Q2
$262K Sell
4,766
-320
-6% -$18.8K 0.01% 511
2025
Q1
$360K Sell
5,086
-6,919
-58% -$465K 0.02% 423
2024
Q4
$789K Buy
12,005
+3,216
+37% +$215K 0.05% 280
2024
Q3
$618K Buy
8,789
+5,435
+162% +$454K 0.05% 287
2024
Q2
$276K Buy
3,354
+1,882
+128% +$157K 0.02% 419
2024
Q1
$129K Buy
1,472
+1,161
+373% +$104K 0.01% 593
2023
Q4
$30K Sell
311
-1,270
-80% -$112K ﹤0.01% 874
2023
Q3
$140K Sell
1,581
-4,248
-73% -$378K 0.01% 593
2023
Q2
$505K Buy
5,829
+2,548
+78% +$240K 0.03% 387
2023
Q1
$319K Sell
3,281
-1,606
-33% -$166K 0.01% 447
2022
Q4
$506K Sell
4,887
-2,443
-33% -$229K 0.02% 381
2022
Q3
$621K Sell
7,330
-3,386
-32% -$301K 0.02% 339
2022
Q2
$888K Sell
10,716
-13,281
-55% -$1.06M 0.03% 303
2022
Q1
$1.85M Buy
23,997
+7,979
+50% +$668K 0.07% 212
2021
Q4
$1.42M Sell
16,018
-29,079
-64% -$2.4M 0.05% 271
2021
Q3
$3.49M Sell
45,097
-1,325
-3% -$105K 0.15% 123
2021
Q2
$3.87M Sell
46,422
-23,334
-33% -$1.85M 0.23% 89
2021
Q1
$5.27M Buy
69,756
+42,758
+158% +$3.49M 0.31% 70
2020
Q4
$2.37M Buy
+26,998
New +$2.14M 0.13% 142

Other funds holding BMRN

Leonteq Securities's BMRN Position: Q3 2026 in Review

Leonteq Securities reduced its BioMarin Pharmaceuticals (BMRN) stake by 38% in Q3 2026, selling an estimated $86.3K and leaving 2,227 shares worth $134K. The position accounts for 0.01% of the portfolio, ranked #601.

Leonteq Securities first reported a position in BMRN in Q4 2020 and has held it in 24 quarters since. The position peaked at $5.27M in Q1 2021. 565 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Leonteq Securities held 2,227 shares of BioMarin Pharmaceuticals worth $134K as of Q3 2026.
  • Leonteq Securities sold 1,371 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $86.3K.
  • BioMarin Pharmaceuticals made up 0.01% of Leonteq Securities's portfolio in Q3 2026, its #601 holding.
  • Leonteq Securities first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 24 quarters since.
  • Leonteq Securities's BioMarin Pharmaceuticals position peaked at $5.27M in Q1 2021.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.